REMINDER/Tissue Banks Convene to Review Safety Standards and New Methods of Tissue Sterilization; New Data Show CLEARANT PROCESS Achieves Highest Level of Tissue Safety.

Business Editors/Health & Medical Writers

REMINDER...for Monday (Aug. 26)

--(BUSINESS WIRE)

WHAT:   A major session at the 26th Annual Meeting of the American
        Association of Tissue Banks (AATB)--New Advances in Tissue
        Sterilization--will examine the growing need for elevated
        industry-wide safety standards and review data from the
        CLEARANT PROCESS(TM), an advanced pathogen inactivation
        technology.

        --  The CLEARANT PROCESS(TM) is the only technology currently
            available that can completely penetrate tissue to destroy
            all types of pathogens and can be applied at any stage of
            processing, including the sterilization of the tissue in
            its final packaging, which, unlike other methods, will
            allow tissue processors to substantiate a sterilization
            claim without harming the integrity and function of the
            tissue. However, to date, the CLEARANT PROCESS(TM) has not
            been widely adopted by tissue banks.

WHY:    Increasing reports of infections caused by tissue
        transplants have given rise to an urgent industry-wide need
        for tissue banks to elevate current safety standards and
        adopt advanced pathogen inactivation technologies, such as
        the CLEARANT PROCESS(TM).

        --  In November 2001, 23 year-old Brian Lykins died after
            receiving a tissue transplant contaminated with Clostridia
            (a type of bacteria), which led to a temporary halt to all
            elective knee surgeries in Minnesota.

        --  Over the past year, the U.S. Centers for Disease Control &
            Prevention (CDC) identified 54 cases of infections,
            including the one death, caused by contaminated tissues,
            and has recommended elevating safety standards and that
            more effective sterilization methods be adopted.

        --  In May 2002, a tissue bank voluntarily recalled its tissue
            due to contamination with Clostridia and two months later
            received a warning letter from the U.S. Food & Drug
            Administration (FDA) citing continued problems with its
            processing procedures.

        --  Last week, the FDA recalled human tissue from a large
            tissue-processing firm bringing the public, medical and
            regulatory concern about tissue safety to an all time
            high.

WHO:    Session presenters and thought leaders are available for
        interview, including perspectives of:

    --  Industry

        --  James Forsell, PhD, AATB Session Moderator, Chair of the
            AATB Musculoskeletal Council and Executive Vice President
            of Tissue Banks International

    --  Physicians With Extensive Tissue Transplant Experience

        --  Warren King, MD, Orthopedic Surgeon, Palo Alto Medical
            Foundation, and Medical Consultant to the Oakland Raiders
            NFL Team in Oakland, California

        --  David Langer, MD, Neurosurgeon, Beth Israel Medical
            Center, New York, NY

    --  Clearant, Inc.

        --  William Drohan, PhD, President

        --  Alain Delongchamp, Chief Operating Officer

        --  Wilson Burgess, PhD, Senior Vice President, Research and
            Development

    --  Government

        --  Lennox Archibald, PhD, Acting Medical Director Epidemic
            Intelligence Exchange, Centers for Disease Control &
            Prevention

WHEN: Monday, August 26, 2002   WHERE: Sheraton Boston Hotel,
      8:00 a.m. to 9:30 a.m.           Grand Ballroom
                                       39 Dalton Street, Boston, MA

    FOR MORE INFORMATION OR TO ARRANGE INTERVIEWS, PLEASE CONTACT:
            Christie Anbar or Amy Covino, Belsito & Company
                            [phone]